Safety and Tolerability of an SQ-Standardized GRAss ALlergy Immunotherapy Tablet (GRAZAX®) in a Real-Life Setting for Three Consecutive Seasons — The GRAAL Trial

Background and Objectives: GRAZAX® (Phleum Pratense, 75000 SQ-T/2800 BAU, ALK, Denmark), an SQ-standardized grass allergy sublingual immunotherapy tablet for the desensitization of grass pollen-induced rhinoconjunctivitis, has been developed to facilitate patient access to specific immunotherapy (SIT), while minimizing the risk of serious treatment-related adverse events. As a minimum duration of 3 years is recommended for SIT treatment, the GRAAL trial aimed to assess the safety profile of GRAZAX® in real-world conditions during long-term treatment of patients with grass pollen-induced allergic rhinoconjunctivitis (ARC).